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Abstract
Acupuncture is widely used for pain treatment in patients with osteoarthritis or low back pain, but molecular mechanisms
remain largely enigmatic. In the early phase of inflammation neutrophilic chemokines direct opioid-containing neutrophils
in the inflamed tissue and stimulate opioid peptide release and antinociception. In this study the molecular pathway and
neuroimmune connections in complete Freund’s adjuvant (CFA)-induced hind paw inflammation and electroacupuncture
for peripheral pain control were analyzed. Free moving Wistar rats with hind paw inflammation were treated twice with
electroacupuncture at GB30 (Huan Tiao - gall bladder meridian) (day 0 and 1) and analyzed for mechanical and thermal
nociceptive thresholds. The cytokine profiles as well as the expression of opioid peptides were quantified in the inflamed
paw. Electroacupuncture elicited long-term antinociception blocked by local injection of anti-opioid peptide antibodies
(beta-endorphin, met-enkephalin, dynorphin A). The treatment altered the cytokine profile towards an anti-inflammatory
pattern but augmented interferon (IFN)-gamma and the chemokine CXCL10 (IP-10: interferon gamma-inducible protein)
protein and mRNA expression with concomitant increased numbers of opioid peptide-containing CXCR3+ macrophages. In
rats with CFA hind paw inflammation without acupuncture repeated injection of CXCL10 triggered opioid-mediated
antinociception and increase opioid-containing macrophages. Conversely, neutralization of CXCL10 time-dependently
decreased electroacupuncture-induced antinociception and the number of infiltrating opioid peptide-expressing CXCR3+
macrophages. In summary, we describe a novel function of the chemokine CXCL10 - as a regulator for an increase of opioid-
containing macrophages and antinociceptive mediator in inflammatory pain and as a key chemokine regulated by
electroacupuncture.
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Introduction
Acupuncture has been shown to significantly reduce pain
intensity in various pain syndromes e.g. in patients with
osteoarthritis [1], low back pain [2] in most, but not all studies
[3]. Indeed, due to large cohort studies in patients with low back
pain and knee pain this treatment is covered by public heath
insurances in some countries including Germany [4]. Despite its
widespread use, the underlying mechanisms of acupuncture-
induced analgesia are still only incompletely understood. Acu-
puncture leads to a down-regulation of pro-inflammatory
cytokines such as tumor necrosis factor (TNF-alpha) and
interleukin (IL)-1beta at the site of inflammation [5,6]. This anti-
inflammatory as well as antinociceptive effect involved activation
of the cannabinoid receptor 2 (CB2) [6]. Endogenous opioid
peptides such as beta-endorphin (END) also could contribute to
acupuncture-induced analgesia. They activate opioid receptors
both at the level of the spinal cord [7,8] as well as on peripheral
sensory neurons at the site of inflammation [9,10]. Acupuncture
triggers END transcription and translational in the inflamed tissue
and this was attenuated by a CB2 antagonists [11].
Opioid-mediated peripheral antinociception has been exten-
sively studied in models of local hind paw inflammation induced
by complete Freund’s adjuvant (CFA) [12]. Opioid-containing
leukocytes migrate into the inflamed tissue, release opioid peptides
such as END, Met-enkephalin (ENK) and dynorphin A (DYN)
and induce antinociception by binding to opioid receptors (m,
MOR; d, DOR and k, KOR) on peripheral nociceptive neurons.
In the early phase of inflammation (first 24 h post induction)
neutrophils are the predominant opioid-containing leukocytes
whereas monocytes/macrophages are relevant at later stages (.
24 h) [13,14]. Chemokines (CXCL2/3) or corticotrophin releasing
hormone can trigger opioid peptide release [14–17]. These
mediators are either locally injected or they were endogenously
released under conditions of stress (cold water swim). The
pathophysiological relevance of peripheral opioid-mediated anti-
nociception was more recently demonstrated since bacterial
products (formyl peptides) at the site of inflammation bind to
formyl peptide receptors on neutrophils leading to tonic release of
opioid peptides and a reduced intensity of inflammatory pain [18].
Studies on chemokines have shown that chemokine receptor
CXCR2 ligands play a dual role in peripheral antinociception;
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they are responsible for both the increased numbers of opioid-
containing CXCR2+ neutrophils to the site of inflammation and
the release of opioid peptides from this leukocyte population [16].
In contrast, the role of chemokines at later stages of inflammation
when monocytes and macrophages are the major opioid-
containing leukocyte population is not well understood. Thus
far, the chemokine receptor CCR2 that is expressed on monocytes
and peripheral sensory neurons and its ligand CCL2 were shown
to act as proalgesic mediators in neuropathic pain and in
inflammation [4].
In our study, we explored the molecular mechanisms of
peripheral opioid-mediated antinociception in late inflammation
and antinociception by electroacupuncture. Specifically, we
addressed i) the regulation of cytokines and chemokines by
electroacupuncture, ii) the role of the chemokine CXCL10 ( = IP-
10, interferon gamma-inducible protein) in CFA inflammation,
and iii) the function of CXCL10, opioid-containing macrophages
as key regulator of electroacupuncture-induced antinociception.
Materials and Methods
Animals and model of inflammation
Animal protocols (REG 69/10) were approved by the govern-
mental animal care committee (Regierung von Unterfranken,
Wu¨rzburg, Germany) and are in accordance with the Interna-
tional Association for the Study of Pain [19]. Experimental
procedures except electroacupuncture treatment were performed
under isoflurane anesthesia. Six to ten male Wistar rats (280–
350 g) per treatment group were injected intraplantarly (i.pl.) with
150 ml of CFA (Calbiochem, San Diego, CA, USA) in the right
hind paw [14].
Electroacupuncture treatment
A reproducible electroacupuncture protocol in free moving rats
performed right after injection of CFA and at 24 h post CFA using
3D image computer modeling was previously established [10].
Rats were randomly divided into CFA+EA (EA) and CFA control
(CFA) group and were carefully habituated within the sterilized
disposable paper cap three days before experiment. Before
needling, the fur above GB30 was shaved on the lower back and
disinfected. Briefly, disposable acupuncture needles (Ø= 0.20 mm,
length = 25 mm, schwa-medico, Ehringshausen, Germany) con-
nected to an electrical stimulator (AS Super_4_digital, schwa-
medico) were slightly inserted into bilateral GB30 (Huan Tiao).
GB30 is widely used to treat sciatica in patients or hind paw pain
in rats located on the junction of lateral 2/3 and medial 1/3 on the
line between the great trochanter and last sacral vertebrae [20].
The needle position was adjusted if sign of direct irritation of a
nerve or blood vessel were noted. The intensity of electroacu-
puncture was delivered in a gradual and intermittent manner of 2–
2.5–3 mA (frequency: 100 Hz, pulse width: 0.1 ms) for 20 min.
The exact intensity for different individuals was flexibly kept
between 2–3 mA. A slight muscle twitching of the entire hind limb
including the paw could be observed as a sign of accurate needling
on sciatic nerve underneath of GB30. Rats were kept conscious
and allowed for complete free mobilization in the cage during the
whole process. For sham treatment needling was performed
without application [10].
Measurement of nociceptive thresholds
Thermal nociceptive thresholds (paw withdrawal latency; PWL)
were obtained by the Hargreaves test (IITC Inc/Life Science,
Italy) [18]. Rats were habituated in the plastic box with a glass
plate underneath for 2–3 d before experiments. The heat of a
radiant bulb was adjusted to obtain a paw withdrawal latency of
20 s in the non-inflamed paw. The required time (s) until paw
withdrawal was taken as thermal nociceptive threshold. The cut
off was set at 30 s to avoid tissue damage. The average of two
measurements (with 20 s intervals) was calculated for analysis.
Mechanical nociceptive thresholds (paw pressure threshold;
PPT) were evaluated with the paw pressure algesiometer (modified
Randall-Selitto test; Ugo Basile, Comerio, Italy) [18]. Rats were
habituated into a sterilized disposable man-made cap for several
days before experiments and were gently held in the cap during
the pain measurements [18]. Increasing pressure (g) was applied to
the dorsal surface of paw until the rat withdrew its paw. The cut
off point was set at 250 g to avoid tissue damage. Measurements
were performed three times (with 10 s intervals) and averages were
calculated. All the behavioral tests were performed in a blinded
manner.
A value of nociceptive threshold lower than that determined in
the contralateral paw usually represents hyperalgesia ( = pain) and
values above contralateral thresholds usually represent antinoci-
ception ( = analgesia) in animals. Strictly speaking full or partial
reversal of hyperalgesia can also be stated as anti-hyperalgesia.
Pharmacologic interventions
To examine the role of opioid peptides, groups of EA-treated
animals were i.pl. injected with anti-opioid peptide antibodies
(anti-END, anti-ENK, or anti-DYN; all rabbit anti-rat IgG
antibodies, Peninsula, CA, US) at 4 d post CFA induced
inflammation. In separate groups of animals, recombinant rat
CXCL10 or rabbit anti-rat CXCL10 (both from Peprotech,
Hamburg, Germany) was i.pl. administered daily for 5 d (day 0 to
4). Optimal doses were established in preliminary experiments or
were based on previous studies [18,21]. Solvent saline or an
identical dose of rabbit IgG was used as a control.
Enzyme-linked immunosorbent assay (ELISA)
Paw tissue was retrieved at 96 h post CFA injection and minced
in ice cold lysis buffer (20 mM imidazole hydrochloride, pH 6.8;
100 mM potassium chloride, 1 mM magnesium chloride, 10 mM
ethylene glycol tetraacetic acid, 1.0% Triton X-100, 10 mM
sodium fluoride, 1 mM sodium molybdate, 1 mM ethylenedi-
aminetetraacetic acid (Sigma-Aldrich, Munich; Merck, Darm-
stadt; Carl Roth GmbH, Karlsruhe, all Germany) with complete
Protease Inhibitor Cocktail (Roche Diagnostics, Mannheim,
Germany). The homogenate was frozen at 280uC. Before
experiment, the homogenate was thawed, incubated at 4uC
overnight, centrifuged at 14,000 g for 10 min and the supernatant
was used for ELISA [13]. ELISA kits were used according to the
manufacturer’s instructions: IL-1alpha, IL-1beta and interferon
(IFN)-gamma (R&D systems, London, UK); CXCL10 (Peprotech,
Hamburg, Germany); TNF-alpha and IL-4 (Invitrogen, Life
Technologies, Darmstadt, Germany) and IL-13 (Abcam, Cam-
bridge, UK).
RNA extraction, cDNA transcription and real-time-
polymerase chain reaction (RT-PCR)
Rat paw tissues at 72 and 96 h post CFA were homogenized
with sterilized stainless steel beads (5 mm, Qiagen, Du¨sseldorf,
Germany) by Tissuelyser (frequency: 20 Hz, Qiagen, Hilden,
Germany) [22]. Total RNA was extracted by using TRIzol
(Invitrogen/Life Technologies, Carlsbad, CA, USA). Purified
RNA (1 mg) was reversely transcribed into cDNA using the
High-Capacity cDNA Reverse Transcription Kit. cDNA was
diluted 10-fold and amplified by RT-PCR with Taqman gene
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expression assays for rat CXCL10 (labeled with FAM, Assay ID:
Rn01413889_g1) and GAPDH (glyceraldhyde-3- phosphate de-
hydrogenase, labeled with VIC) as a housekeeping gene (FAM and
VIC are compatible fluorescein-based 59 end reporter dye, the
sequence of each primer is confidential from Applied Biosystems/
Life Technologies). Assays were performed according to the
manufacturer’s recommendations using 50 cycles, annealing and
extension 1 min at 60uC (7300 System Sequence Detection
Software v1.4.0). RT-negative control was applied by all the
reagents except the enzyme mix ‘ABsolute QPCR ROX Mix’
(Thermo Fisher Scientific GmbH, Heiligenfeld, Germany) to
access the genomic DNA contamination in reverse transcription
reaction. Results were calculated using the 2DDCT method for
relative quantification. GAPDH was selected as a reference for
quantification due to the optimal stable expression in inflamed and
non-inflamed paw tissue compared to beta-actin and 18SrRNA in
our preliminary experiments (data not shown).
Immunohistochemistry
Three rats/group at 96 h post CFA were deeply anesthetized
with isoflurane and perfused transcardially with 0.1 M phosphate-
buffered saline, pH 7.4, and with cold phosphate-buffered saline
containing 4% paraformaldehyde pH 7.4 (fixative solution) [23].
The subcutaneous tissue adjacent to the skin was dissected from
plantar surfaces of both hind paws, post-fixed in the fixative
solution, and cryoprotected in 10% sucrose solution at 4uC
overnight, embedded in tissue-Tek compound (OCT, Miles Inc.,
Elkhart, IN), and frozen. Seven-micrometer-thick sections were
prepared on cryostat and mounted on gelatin-coated slides. For
double immunostaining, the tissue sections were incubated with a)
polyclonal rabbit anti-END or –ENK or –DYN (1:1000; all from
Peninsula Laboratories, Merseyside, UK) in combination with
monoclonal mouse anti-CD68 (ED1, 1:400; Serotec, Du¨sseldorf,
Germany) or b) mouse anti-CXCR3 (1:500, Biosource, Inc., San
Diego, USA) in combination with polyclonal rabbit anti-rat
macrophage (1:200, Cedarlane Laboratories, Ontario Canada).
Texas red conjugated goat anti-rabbit antibodies in combination
with FITC conjugated donkey anti-mouse antibodies were used as
secondary antibodies (all Vector Laboratories, Burlingame, CA).
Finally, the tissues were stained with 49,6 diamidino-2-phenylin-
dole (DAPI) and mounted on vectashield (Vector Laboratories).
To demonstrate specificity of staining, omission of the primary
antibody was used. The contralateral (contra.) paws without
inflammation were stained as negative control (data not shown).
A total of 3 samples from the inflamed paw tissue were imaged
in each group, and counting of single- and double-labeled cells was
done on confocal images randomly taken from three view fields in
each section. Cell counting was performed by a blinded
investigator using NIH Image J software (Bethesda, MD, USA).
The percentage of double-labeled cells per single-labeled cells was
used for statistical analysis.
Experimental protocols
Before experiments, all animals were randomly divided to
CFA+EA, CFA+ sham and CFA control.
1. Antibodies against opioid peptides (END: 2 mg, ENK:
1.25 mg, DYN: 1 mg) were applied (i.pl.) on CFA+EA treated rats
at 96 h post CFA. Mechanical and thermal nociceptive threshold
changes were assessed 5 min post injection. Control animal
received IgG (2 mg).
2. A cytokine array (data not shown) for detecting the relative
signals of 29 cytokines/chemokines was performed with paw tissue
from CFA or CFA+EA treated rats. ELISA further quantified the
protein levels of selected promisingly expressed cytokines/
chemokines from cytokine array. CXCL10 was chosen as the
targeted chemokine and applied for all subsequent studies due to
the most significant upregulation by CFA+EA treatment as well as
our former investigations on antinociceptive property of other
CXC-chemokines [16].
3. Nociceptive thresholds were daily determined from CFA rats
treated with CXCL10 (i.pl., 0.2 ng) or CFA+EA rats treated with
the CXCL10 blocking antibody (i.pl., 2 mg) daily from 0–4 d. (a)
In selected experiments rats were injected with anti opioid peptide
antibodies on day 4 and nociceptive thresholds measured
thereafter. (b) Double immunohistochemistry staining on paw
tissue sections was conducted for macrophages with either
CXCR3 (receptor of CXCL10) or END/ENK/DYN on day 4
after treatment.
Statistical analysis
All data were presented as mean 6 SEM. Data of nociceptive
thresholds were given as raw values. Multiple measurements at
one time point between two or more than two groups were
analyzed by t-test or one way analysis of variance (ANOVA),
respectively, e.g. t-test was used for analysis of two groups with one
variable factor (e.g. cytokine ELISA from CFA and CFA+EA
groups), and one way ANOVA was applied for comparison of
multiple groups at one time point (opioid peptide staining from
CFA, CFA+EA, CFA+ sham groups). Multiple measurements at
different time points between two or more than two groups were
analyzed by two way repeated measurement (RM) ANOVA (e.g.
all behavioral experiments). Holm-Sidak method was used for one
way ANOVA and Student-Newman-Keuls Method was used for
two way RM ANOVA. *P,0.05 or **P,0.01 was regarded as
statistically significant.
Results
Antinociception by electroacupuncture is linked to
peripheral opioid peptides
In a previous study, at 96 h CFA, electroacupuncture at GB30
caused antinociception in CFA inflammation which was fully
blocked by peripheral injection (i.pl.) of the opioid receptor
antagonist naloxone at the site of inflammation [10]. Sham-EA
treatment (needling without application of current) did not elicit a
comparable antinociceptive effect in both mechanical and thermal
nociceptive threshold tests (Fig. 1A, E). Local injection of
antibodies against the opioid peptides END or ENK significantly
inhibited electroacupuncture-mediated mechanical and thermal
antinociception at 5 min post injection compared to isotype
control antibody (Fig. 1B, C, F, G, doses according to [18]).
There was no significant difference between CFA baseline paw
pressure threshold at 96 h and CFA+EA and anti-END or anti-
DYN paw pressure thresholds. Anti-END or anti-ENK injection
in CFA+EA rats thermal thresholds even more than baseline CFA
levels at 96 h. Simultaneous injection of anti-END and anti-ENK
antibodies did not cause an additive effect (data not shown).
Antibodies against DYN (i.pl., doses according to [21]) completely
blocked antinociception to mechanical (Fig. 1H) but not thermal
stimuli (Fig. 1D). Nociceptive thresholds of non-inflamed paws
from the same experiments in Fig. 1 were not significantly altered
as displayed in Fig. S1, manifesting the peripheral other than the
central opioid peptide-related mechanism involved in the study.
Due to the more pronounced effects of EA on mechanical
nociceptive thresholds and different mechanisms of thermal and
mechanical hyperalgesia we focused on these in subsequent
experiments.
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Electroacupuncture regulates expression of certain
cytokines in the inflamed paw
At 96 h CFA, based on a cytokine array detecting a total 29
cytokines (data not shown), we selectively quantified the protein
level of several positive cytokines. Pro-inflammatory cytokines
including TNF-alpha and IL-1beta (Fig. 2A, C) were significantly
downregulated by electroacupuncture whereas IL-1alpha (Fig. 2B)
was unaltered. The anti-inflammatory cytokine IL-4 remained
unchanged whereas IL-13 was significantly upregulated (Fig. 2D,
E). Interestingly, the only pro-inflammatory cytokine that was
significantly upregulated was IFN-gamma (Fig. 2F).
CXCL10 expression and increased numbers of opioid-
containing macrophages are associated with
electroacupuncture
CXCL10 is a chemokine stimulated by IFN-gamma [24]. Since
IFN-gamma was the only pro-inflammatory cytokine upregulated
by electroacupuncture, we focused our subsequent experiments on
CXCL10. Electroacupuncture significantly upregulated CXCL10
on both the protein (Fig. 3A) and mRNA level (Fig. 3B). No
CXCL10 protein increase was seen in sham-treated animals.
Neutrophils are an important source of opioid peptides released
in the early phase of CFA-inflammation (up to 24 h) whereas
macrophages are considered mainly responsible for peripheral
opioid peptide-mediated antinociception at later stage of inflam-
mation (48–96 h). T cells constitute only a small subpopulation of
infiltrating leukocytes (,5%) [14]. Since CXCL10 exclusively
binds to the chemokine receptor CXCR3 [25], we analyzed the
co-expression of CXCR3 with a rabbit anti-rat macrophage serum
at the site of inflammation with or without concomitant
electroacupuncture. CXCR3 was expressed on the vast majority
of infiltrating macrophages (Fig. 3C). Furthermore, the percent-
age of CXCR3+ expressing macrophages was significantly
increased by electroacupuncture (Fig. 3D).
CXCL10 reverses CFA-induced mechanical hyperalgesia
via peripheral opioid peptides
Chemokines like CXCL1 and CXCL2/3 play a dual role in
peripheral opioid peptide mediated antinociception, because
Figure 1. The antinociceptive effect of electroacupuncture (EA) via opioid peptides at the site of inflammation. Wistar rats were
injected with CFA i.pl. for 48–96 h and treated with CFA and electroacupuncture (EA) at GB30 at 0 and 24 h (day 0 and 1, 100 Hz, 20 min, 2–3 mA)
(CFA+EA). [A, E] In previous studies, sham-EA rats did not show significant difference in both mechanical and thermal nociceptive thresholds
measurements at 0, 48, 72 and 96 h. Data were presented as mean 6 SEM (*p,0.05, CFA+EA versus CFA; $p,0.05, CFA+EA versus CFA+ sham; #p,
0.05, CFA+ sham versus CFA; Two-way RM ANOVA, Student-Newman-Keuls). We therefore omitted sham-EA treatment in following studies. Anti-END
(2 mg [B, F], anti-ENK (1.25 mg [C, G]) or anti-DYN (1 mg [D, H]) was locally injected (i.pl.) at 4 d post CFA and concomitant twice EA treatment (black
circles). Two control groups were added: injection with identical doses of nonspecific anti-rabbit IgG (white circle) or for comparison CFA without EA
(black triangle). Paw withdrawal latency (thermal nociceptive thresholds [A–D]) or paw pressure thresholds (mechanical nociceptive thresholds [E–
H]) were determined before (BL: baseline) and 5 min after injection (treated). All the data are presented as mean 6 SEM (n= 6 per group, *p,0.05,
**p,0.01, CFA+EA+IgG versus CFA+EA+anti-END/ENK/DYN; Two-way RM ANOVA, Student-Newman-Keuls).
doi:10.1371/journal.pone.0094696.g001
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they recruit opioid-containing neutrophils and trigger opioid
peptide release via its receptor CXCR2 [16]. To address
whether CXCL10 was able to attenuate inflammatory pain by
CFA via increased numbers of opioid containing cells we
performed multiple injection of CXCL10. Repeated daily
administration of 0.2 ng CXCL10 (based on a preliminary
dose-finding study, data not shown) elicited sustained mechan-
ical antinociception at 48, 72 and 96 h (Fig. 4A). CXCL10-
mediated antinociception was fully reversed by the concomi-
tant i.pl. administration of CXCL10 with anti-END, anti-
ENK, or anti-DYN at 96 h (Fig. 4B). In parallel, repeated
chemokine injection was associated with a significant increase
in ED1+ macrophages co-expressing the opioid peptides END,
ENK, and DYN in comparison to solvent control (Fig. 4C–E).
More ED1+ macrophages expressed ENK (almost 72%)
compared to END (63%) and DYN (55%) (Fig. 4F). No
change was seen in rats treated with solvent.
Electroacupuncture increases ligand availability
Next, we tested whether electroacupuncture affects the accu-
mulation of opioid peptide. Electroacupuncture was associated
with a significant increase in the number of ED1+ macrophages
co-expressing the three opioid peptides END, ENK and DYN
(Fig. 5A, B, C). More ED1+ macrophages expressed ENK (almost
75%) compared to END (65%) and DYN (60%) (Fig. 5D). No
change on the co-expression of opioid peptides and ED1 was seen
in sham treated rats.
Electroacupuncture-induced antinociception and
increased numbers of opioid-containing macrophages is
prevented by blockade of CXCL10
Since electroacupuncture-elicited antinociception correlated
with the number of opioid-containing macrophages, we examined
whether CXCL10 was a key regulator. Daily injections of anti-
CXCL10 significantly decreased the pain threshold at 48–96 h
post CFA and abolished the electroacupuncture-induced anti-
nociception (Fig. 6A). Furthermore, multiple injections of the anti-
CXCL10 significantly reduced the number of ED1+ macrophages
co-expressing the opioid peptides END, ENK, and DYN (Fig. 6B,
C, D) stimulated by electroacupuncture. The percentage of ED1+
macrophages expressed END was reduced to 53% compared to
ENK (43%) and DYN (44%) (Fig. 6E). No change was seen in
rats treated with isotype control antibody.
Discussion
Acupuncture is widely used as an alternative analgesic therapy
in a broad range of pain syndromes. Despite its widespread use the
role is often doubted and attributed to placebo effects. Indeed, the
underlying molecular mechanisms of pain control are not well
understood. In our study electroacupuncture suppressed selected
pro- and enhanced anti-inflammatory cytokines in a model of
inflammatory pain in rats. In contrast to this pattern, EA increased
the production of the cytokine IFN-gamma and the chemokine
CXCL10 at the site of inflammation leading to an increase in
opioid-containing CXCR3+ macrophages. Macrophage-derived
opioid peptides could activate opioid receptors on peripheral
Figure 2. Differential alterations in pro- and anti-inflammatory cytokines in inflamed paw tissue by electroacupuncture (EA). Rats
were injected with CFA treated with (CFA+EA) or without (CFA) EA. Based on the results from pilot experiments for immune array of 29 cytokines
(data not shown), [A–F] pro- and anti-inflammatory cytokines including TNF-alpha, IL-1alpha, IL-1beta, IFN-gamma, IL-4 and IL-13 in the paws were
selectively quantified by ELISA after 96 h CFA. Data are presented as mean 6 SEM (n= 5–10 per group, *p,0.05, CFA+EA versus CFA; t-test).
doi:10.1371/journal.pone.0094696.g002
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Figure 3. Upregulation of CXCL10 and an increase of CXCR3+macrophages in inflamed paw tissue by electroacupuncture (EA). Rats
were injected with CFA and treated with (CFA+EA), (CFA+sham) or CFA only. On day 4 (96 h), CXCL10 was quantified by ELISA [A] and semi-
quantitative RT-PCR (72 and 96 h) in subcutaneous paw tissue ([B] noninflamed contralateral paw (contra.) is only shown as a negative control). Data
are presented as mean 6 SEM (For ELISA: n = 6 per group, *p,0.05, one way ANOVA, Holm-Sidak method; For RT-PCR: n = 6 per group, *p,0.05,
CFA+EA versus CFA; t-test). [C] Tissue sections were stained with rabbit anti-rat macrophage serum (red), mouse anti-rat CXCR3 antibody (green) and
DAPI. The arrows are pointing at CXCR3 expressed macrophages. Representative sections are shown, arrows pointing on double positive cells (scale
bar: 50 mm). [D] The percentage of macrophages and opioid positive cells was analyzed. All data are presented as mean6 SEM (n = 3 per group, *p,
0.05, CFA+EA versus CFA; t-test).
doi:10.1371/journal.pone.0094696.g003
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Figure 4. Opioid peptide–dependent sustained antinociception and increase opioid peptide expressed macrophages by repeated
CXCL10 injection. Rats were i.pl. injected with CFA and daily with CXCL10 (0.2 ng) or solvent control. [A] Mechanical nociceptive thresholds were
Chemokine and Opioid Peptide in Acupuncture
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sensory neurons and suppressed inflammatory pain. Taken
together we identified a new molecular pathway of acupuncture-
induced analgesia.
Effects of electroacupuncture on the peripheral opioid
system and on cytokine production
Endogenous opioid peptides inhibit pain both in the central
nervous system and in the periphery. Acupuncture triggers the
release of opioid peptides at the level of the spinal cord and in the
brain leading to activation of MOR and sometimes other opioid
receptors [7,26–29]. In the periphery, opioid peptide-induced
antinociception seems to involve MOR, DOR and KOR at the
site of inflammation [9,10,30]. There are some hints that
acupuncture regulates the expression of the END in immune cells
and in keratinocytes via activation of the cannabinoid receptor
CB2 [11]. We now extended these findings by demonstrating that
electroacupuncture stimulated the increased numbers of leuko-
cytes containing the three opioid peptides END, ENK, and DYN
and that all three opioid peptides mediated antinociception to
thermal and mechanical stimuli (similar to stress (cold water swim)-
induced antinociception [12]). In our study, DYN did not
contribute to thermal antinociception induced by acupuncture.
Anti-END and anti-ENK treatment even lowered thermal
nociceptive thresholds more than CFA baseline at 96 h possibly
due to endogenous tonic release of opioid peptides in thermal
hyperalgesia [18]. In accordance with our study here, other groups
also observed that electroacupuncture better controls mechanical
than thermal hyperalgesia in inflammatory pain [31], probably
due to different mechanisms and receptors controlling thermal and
mechanical pain.
In addition to the upregulation of opioid peptides, acupuncture
was previously claimed to suppress the production of the pro-
inflammatory cytokines TNF-alpha, IL-1beta and IL-6 in inflam-
matory pain [6,11]. Studies in other models (asthma, trauma)
demonstrated that Th1 cytokines such as IL-2 and IFN-gamma
were increased whereas Th2 cytokines such as IL-4, IL-10 and IL-
13 were suppressed [32–34]. In our model of inflammatory pain,
electroacupuncture significantly attenuated IL-1beta and TNF-
alpha as well as selectively upregulated the Th1 cell type cytokine
IFN-gamma. In contrast to the findings in models of asthma and
trauma, the Th2 cytokine IL-4 was unchanged and IL-13 was
upregulated indicating the activation of both Th1 and Th2 cell
signaling by electroacupuncture. Therefore, differential effects of
EA on cytokines are observed in different models. Despite the
suppression of pro-inflammatory cytokines we and others [6]
found that the number of infiltrating opioid peptide-containing
leukocytes (i.e. macrophages) was significantly increased by
electroacupuncture. In line with our previous studies [13,14] T
cells were almost absent at the site of CFA-induced inflammation
(data not shown). In summary, our study in part supports the
previously described anti-inflammatory effects of electroacupunc-
ture, but some pro-inflammatory cytokines like IFN-gamma and
CXCL10 seem to be upregulated in inflammatory pain.
Chemokines in inflammation and nociception
In our model of inflammatory pain, the expression of the
chemokine CXCL10 and, in parallel, the numbers of macrophages
expressing the corresponding chemokine receptor CXCR3 were
significantly upregulated by electroacupuncture. Few studies
examined the role of electroacupuncture on chemokine expression.
It was reported electroacupuncture augmented the production of
the chemokine CXCL12 (stromal cell-derived factor-1alpha) in
cerebral ischemic injury [35] whereas the production of CCL2
(monocyte chemotactic protein-1) was downregulated in adipose
tissue without any accompanying inflammation [36]. While these
studies focused on acupuncture, the role of chemokines in
hyperalgesia and antinociception has been studied on more general
level. The monocytic chemokine CCL2 and its corresponding
receptor CCR2 were shown to be proalgesic mediators in
neuropathic and other pain models [37]. Interestingly, chemokine
receptors (including CCR2 and CXCR4) could interact with
receptors involved in antinociception (MOR) or inflammation
(adenosine A2A receptor). Activation of one receptor leads to the
trans-deactivation of the other. Crosstalk between chemokines and
neuronal receptors bridges immune and nervous systems [38].
Studies examining the chemokine-mediated selective recruitment of
isolated leukocyte subpopulations to non-inflamed skin demonstrat-
ed that the monocytic chemokine CCL2 and the neutrophilic
chemokine CXCL1 or CXCL2/3 induced recruitment of the
respective leukocyte population, but while nociceptive thresholds
were unchanged by CXCL2/3 [39], CCL2 elicited hyperalgesia
[23,40]. The role of CXCL10 in pain is not very well examined.
Toll like receptor ligands can induce expression and production of
pro-inflammatory chemokines and cytokines including CXCL10 or
e.g. IL-1alpha, IL-1beta, and PGE2 in dorsal root ganglia neurons,
which in part have previously been shown to increase pain [41]. In
summary, the role of cytokines and chemokines in the generation of
hyperalgesia or antinociception depends on the model and the state
of inflammation.
The broad spectrum of CXCL10-mediated actions in
inflammation
Electroacupuncture augmented the CXCL10 expression both
on the transcriptional and translational level and increased the
number of opioid containing CXCR3+ macrophages as well as
long-lasting antinociception. Repeated injections of CXCL10
reversed hyperalgesia in CFA rats. Similarly, repeated anti-
CXCL10 in EA-treated animals lessened the antinociceptive effect
of EA. CXCL10 is upregulated by IFN-gamma, which was also
increased after treatment with electroacupuncture. CXCL10 is a
chemoattractant for activated T cells, monocytes/macrophages,
dendritic cells and microglia [24]. In addition to recruiting
inflammatory cells, CXCL10 induced astroglial proliferation and
is directly neurotoxic e.g. in the HIV-1 neuropathogenesis [42].
Interestingly, the CXCL10/CXCR3 interaction played an
important role in tuberculosis. Both tuberculosis and CFA-induced
hind paw inflammation are caused by different strains of
mycobacteria. CXCL10 production was upregulated in macro-
determined daily before each injection. Data were presented as mean 6 SEM (n= 6 per group, *p,0.05, **p,0.01, CFA+CXCL10 versus CFA+solvent;
Two-way RM ANOVA, Student-Newman-Keuls). [B] Anti-END (2 mg, anti-ENK (1.25 mg) or anti-DYN (1 mg) was locally injected (i.pl.) at 4 d post CFA on
rats with repeated injection of CXCL10 (0.2 ng). Identical doses of anti-rabbit IgG were used as control. Data were presented as mean 6 SEM (n = 6
per group, *p,0.05, **p,0.01, CFA+CXCL10+IgG versus CFA+CXCL10+anti-END/ENK/DYN; Two-way RM ANOVA, Student-Newman-Keuls). [C]
Immunohistochemical staining of paw tissue was performed at 96 h with a mouse anti-ED1 (CD68) macrophage antibody (green) and with rabbit
anti-END, anti-ENK or anti-DYN antibodies (all was marked red) as well as DAPI. Representative sections are shown. Arrows pointing at double positive
cells. (scale bar: 50 mm). [D] The percentage of END/ENK/DYN+ and ED1+ was quantified. All the data are presented as mean 6 SEM (n= 3 per group,
*p,0.05, CFA+ solvent versus CFA+CXCL10; t-test).
doi:10.1371/journal.pone.0094696.g004
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phages (and to a lesser degree in dendritic cells) by mycobacterium
tuberculosis in vitro and in vivo [43]. This is a hallmark of active –
but not latent – infection [44] similar to our study of CFA
inflammation with heat killed and dried mycobacteria in oily
solution as a nonspecific active inflammation. Furthermore,
CXCL10 regulates the recruitment of CXCR3+ macrophages to
Figure 5. EA enhanced the recruitment of opioid-containing macrophages. Rats were injected with CFA with (CFA+EA), (CFA + sham) or
without (CFA) EA treatment for 4 days. Immunohistochemical staining was performed for mouse anti-CD68 macrophages (green) and rabbit [A] anti-
END, [B] anti-ENK or [C] anti-DYN antibodies respectively (red). DAPI (blue) was used to recognize cell nuclei (Representative sections are shown by
arrows, scale bars: 50 mm). [D] The percentage of ED1 and opioid positive cells was quantified. All the data are presented as mean 6 SEM (n= 3 per
group, *p,0.05, one way ANOVA, Holm-Sidak method).
doi:10.1371/journal.pone.0094696.g005
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Figure 6. Neutralization of CXCL10 fully reversed electroacupuncture (EA)-induced antinociception and increase of opioid-
containing monocytes/macrophages. [A] Rats with CFA inflammation and EA treatment were daily i.pl. injected with an antibody against
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the vessel wall [45]. In contrast in our CFA model, macrophages
were the predominant leukocyte population, T cells were virtually
absent (,5%) and NK cells have thus far not been studied [13,14].
Thus, CXCL10 seemed to preferentially interact with opioid-
containing CXCR3+ macrophages.
The novel role of CXCL10 – a key regulator of
antinociception in acupuncture
Repeated daily injection of CXCL10 conferred sustained
antinociception and lead to a parallel increase in the number of
opioid peptide-expressing macrophages. Our data favor the
hypothesis that electroacupuncture influenced the transcription
and translation of CXCL10. How could this be mediated? One
obvious candidate would be adenosine since manual acupuncture
triggers its release and antinociception is mediated by adenosine
A1 receptors [46]. However, adenosine receptor activation
decreased, rather than increased CXCL10 production in macro-
phages [47]. Alternatively, cannabinoid receptors could be
involved since they contributed to acupuncture-induced antinoci-
ception [5,6]. However, they also suppressed inflammation and
downregulated chemokines at least in keratinocytes [48]. Although
the immune regulation of peripheral acupuncture-induced anti-
nociception appears well understood, the molecular link between
the peripheral nervous system (presumably activated by acupunc-
ture) and the immune regulation remains enigmatic to be solved.
Availability of opioid receptors and ligands for pain
control
Previously, expansion of opioid-containing neutrophils by
hematopoietic factors [22] or enhanced recruitment by local
injection of neutrophilic chemokines [49] did not enhance
peripheral opioid-mediated antinociception in early stages of
inflammation since opioid receptor expression was limiting
antinociception. In addition electroacupuncture did not further
alter the expression of opioid receptors in the inflamed paw (data
not shown). In contrast to the findings of expansion or recruitment
of opioid-containing neutrophils, enhanced recruitment of opioid-
containing macrophages induced antinociception in later stages of
inflammation probably because the opioid receptors are already
upregulated after 4 d of inflammation and not fully occupied by
the available ligands. Importantly, neutralization by an anti-
CXCL10 antibody time-dependently inhibited electroacupunc-
ture-elicited antinociception by daily injection. It also largely
suppressed the increased numbers of opioid-containing macro-
phages. In summary, intensity of antinociception is regulated
differently during inflammation. Antinociception is limited by
opioid receptor availability in early and ligand availability (i.e.
opioid peptides) in late inflammation. Accordingly, increased
numbers of opioid-containing leukocytes enhance antinociception
in late but not in early inflammation.
Taken together, our data suggest that electroacupuncture
enhances CXCL10 production at the site of inflammation and
stimulates peripheral opioid peptide-mediated antinociception.
Furthermore CXCL10 itself appears to trigger an increased
number of opioid-containing monocytes/macrophages at the site
of inflammation without acupuncture. Our data suggest that
CXCL10 appears to be a key antinociceptive mediator also in
electroacupuncture-mediated analgesia.
Supporting Information
Figure S1 [A–H] Nociceptive thresholds of non-in-
flamed paws in Fig. S1 were measured as contralateral
controls. No statistical difference was observed between each
group at given time points. All the data are presented as mean 6
SEM (n= 6 per group, two way RM ANOVA).
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